|Bid||40.61 x 800|
|Ask||40.63 x 800|
|Day's Range||40.59 - 41.45|
|52 Week Range||29.01 - 44.95|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||19.87|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.50|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to exhibit its injectable, HA-based, surgical bone repair therapy at the 2019 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting being held July 11-14 in Boston, Massachusetts at the Hynes Convention Center. “We’re excited to attend this year’s AOSSM Annual Meeting and showcase our HA-based bone repair therapy, which we will be launching in the U.S. this quarter,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. The AOSSM Annual Meeting focuses on providing information on frontline research to the orthopedic sports medicine community, allowing attendees to meet, educate and connect with top physicians in the field of sports medicine.
Anika Therapeutics, Inc. today announced that the Company plans to issue its second-quarter 2019 financial results after the close of the market on Wednesday, July 24, 2019 and hold its investor conference call on the same day, Wednesday, July 24, 2019, at 5:00 p.m.
Industry veteran brings extensive experience leading business development groups
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.